Table 1.
Pretreatment characteristics
| Patient characteristics | 5 fractions (n = 119) |
12 fractions (n = 121) |
|---|---|---|
| Age (y) | ||
| Median | 64 | 66 |
| Range | 48-77 | 50-79 |
| Q1-Q3 | 59-69 | 60-70 |
| Race | ||
| Asian | 1 (1%) | 3 (3%) |
| Black | 11 (9%) | 10 (8%) |
| White | 106 (89%) | 105 (87%) |
| Unknown | 1 (1%) | 3 (3%) |
| Ethnicity | ||
| Hispanic or Latino | 4 (3%) | 3 (3%) |
| Not Hispanic or Latino | 113 (95%) | 115 (95%) |
| Unknown | 2 (2%) | 3 (3%) |
| Zubrod performance status | ||
| 0 | 112 (94%) | 117 (97%) |
| 1 | 7 (6%) | 4 (3%) |
| Clinical N stage | ||
| N0 | 84 (70.6%) | 92 (76%) |
| NX | 35 (29.4%) | 29 (24%) |
| Clinical T stage | ||
| T1a | 2 (2%) | 0 (0%) |
| T1c | 96 (81%) | 100 (83%) |
| T2 | 1 (1%) | 0 (0%) |
| T2a | 20 (17%) | 21 (17%) |
| Treatment techniques/machine* | ||
| All linear accelerator–based treatment (excluding Cyberknife) | 92 (77%) | 95 (79%) |
| Cyberknife | 27 (23%) | 26 (22%) |
| PSA | ||
| Median | 5.6 | 5.5 |
| Range | 0.71-9.9 | 1.69-9.99 |
| Q1-Q3 | 4.5-7.3 | 4.23-6.93 |
| Serum testosterone (ng/mL) | (n = 108) | (n = 110) |
| Median | 257.5 | 265.5 |
| Range | 3.11-667.4 | 0-788 |
| Q1-Q3 | 14.6-390.5 | 12.9-410 |
Abbreviations: PSA = prostate-specific antigen; Q1 = first quartile; Q3 = third quartile.
*
Stratification factor.